DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Huntington disease — screening already-approved drugs against its 40-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHuntington disease maps to a 40-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for huntington disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
solute carrier family 2 member 3 (SLC2A3) — SLC2A3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4ZW9 · 1.502 Å · ligand (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate (OLC). Experimental structure, not a prediction.
What the evidence adds up to
No disease-modifying therapy exists for Huntington disease. A 2025 analysis of 8,071 Enroll-HD natural history participants and 260 placebo-arm participants from the GENERATION HD1 phase 3 trial found that total functional capacity scores in the placebo arm aligned with predicted natural history, showing no significant placebo response. However, total motor scores improved significantly after baseline, persisting until week 69 before converging to natural history predictions at weeks 85 and 101, suggesting a placebo effect. Cognitive scores on the symbol digit modalities test and Stroop word reading test showed sustained improvement up to week 101, likely due to practice effects from more frequent testing in the trial compared to annual assessments in the natural history study. The composite Unified Huntington’s Disease Rating Scale score was influenced by both placebo and practice effects.
A 2009 review of murine models noted that no therapy has proved effective in modifying the disease course or improving survival in Huntington disease. The review evaluated the strengths and weaknesses of mouse models in reproducing Huntington pathology and their role in preclinical trials for novel therapeutic agents. A 2024 review stated that medications such as tetrabenazine target physical symptoms by reducing movement, and antidepressants and antipsychotics are used to manage psychotic and cognitive symptoms, but there is no known cure.
The 2025 analysis relied on limited placebo data from a single trial and may not generalise to other populations or designs. The 2009 review did not report any positive preclinical results from murine models. The 2024 review did not provide quantitative efficacy data for any treatment. What remains missing is a disease-modifying therapy, adequately powered placebo-controlled trials that account for practice effects and long-term placebo responses, and validated patient stratification methods to distinguish true drug effects from these confounders.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2025 · 4 citations · open access
Modeling Disease Progression and Placebo Response in Huntington Disease
AbstractBACKGROUND AND OBJECTIVES: Huntington disease is a rare neurodegenerative disorder with no disease-modifying therapies. This study aimed to quantify longitudinal changes in Unified Huntington's Disease Rating Scale (UHDRS) scores and evaluate their susceptibility to placebo response, enhancing our understanding of disease progression and ability to optimize future trials. METHODS: We used data from the Enroll-HD natural history study (NCT01574053) and the GENERATION HD1 phase 3 clinical trial (NCT03761849) to model disease progression and placebo response for UHDRS scores, which are commonly used to evaluate disease progression in clinical trials. RESULTS: We included 8,071 Enroll-HD participants (mean baseline age: 51.4 years, 51.5% female) to develop a natural history progression model using baseline characteristics as predictive covariates. This model was then used to predict natural history progression of 260 participants from the GENERATION HD1 placebo arm (mean baseline age: 48.7 years, 43.5% female).The progression measured by Total Functional Capacity (TFC) in the GENERATION HD1 placebo arm aligned with predicted natural history (within 95% CI), indicating no significant placebo response. However, significant improvements (outside the 95% CI of the model) were observed after baseline for Total Motor Score (TMS), Symbol Digit Modalities Test (SDMT) score, and Stroop Word Reading (SWR) score. The improvement in TMS persisted until the end of the dosing period (week 69), converging to natural history predictions at subsequent follow-up visits (weeks 85 and 101), suggesting a placebo effect. By contrast, cognitive scores (SDMT and SWR) showed sustained significant improvement (outside the 95% CI) up to the final follow-up visit at week 101, likely due to practice effects from the more frequent testing schedule in GENERATION HD1 compared with the annual assessments in Enroll-HD. Consequently, the composite UHDRS (cUHDRS) score, a linear combination of TFC, TMS, SDMT, and SWR, is influenced by both placebo and practice effects. DISCUSSION: Our results suggest that clinical scores in Huntington disease trials are susceptible to long-term placebo responses. These effects should be considered in future trial designs, especially when comparing trial data with natural history studies. Although based on the largest Huntington's trial, our results rely on limited placebo data and may not generalize to other trials with different populations, treatments, and designs.
AbstractHuntington disease is an inherited neurodegenerative disorder associated with inexorable progression. To date, no therapy has proved effective in modifying the disease course or improving survival. We present here an evaluation of our most valuable asset in the development of a cure – the mouse model. In particular, we will reflect on the relative strengths and weaknesses of current models in reprising Huntington disease pathology, evaluate their role in the development of novel therapeutic agents through preclinical trials and consider their future impact on Huntington disease research.
Research Journal of Pharmacology and Pharmacodynamics · 2024 · 0 citations
Huntington’s Disease: A Review of The Clinical Survey and Therapeutics Management of Neuropsychiatric Drug
AbstractHuntington disease (HD) is an autosomal neurodegenerative disease caused by the excess of CAG trinucleotide repeats in the Huntington gene (HTT). In addition to various symptoms such as chorea, movement disorders, cognitive impairment and psychosis, patients with HD may also experience behavioral and physical changes. Although there is no known cure for HD, there are many ways to try to reduce symptoms and slow the progression of the disease. Medications such as tetrabenazine and tetrabenazine target physical symptoms by reducing movement. Antidepressants and antipsychotics are also used to manage the psychotic and cognitive symptoms of HD. The purpose of this review is to discuss the effectiveness of current HD treatments and explore the progress in clinical research on emerging HD treatments.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
